Assessing Clinical Effectiveness of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam in Bacteremia: A Systematic Review and Meta-Analysis. [PDF]
Mohammad S, Albalas M, Al-Ahmad MM.
europepmc +1 more source
Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis. [PDF]
Gatti M, De Paola R, Giorgi B, Pea F.
europepmc +1 more source
Methods: The study included non-COVID-19 adult hospitalized patients with MDR-PSA PNA in the PINC AI Healthcare Database (2016-22) who received ceftolozane/tazobactam or ceftazidime/avibactam within 3 days of index culture for ≥2 days.
Obi, Engels N. +5 more
core +1 more source
Investigation of Carbapenemase Resistance Genes and Plasmid-Mediated Quinolone Resistance Genes in Ceftolozane/Tazobactam-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> Isolates. [PDF]
Çınar C +6 more
europepmc +1 more source
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Multidrug-Resistant <i>Klebsiella pneumoniae</i>: A Retrospective Single-Center Study in China. [PDF]
Yi J +5 more
europepmc +1 more source
<i>In vivo</i> efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant <i>Pseudomonas aeruginosa</i> carrying the AmpC E219K substitution. [PDF]
Rodríguez-Coello A +14 more
europepmc +1 more source
Long-term trends in ceftolozane-tazobactam susceptibility among gram-negative pathogens in the United States: a nine-year SMART analysis (2016-2024). [PDF]
Wise MG +6 more
europepmc +1 more source
Carbapenem resistance and susceptibility to Ceftazidima/avibactam and Ceftolozane/tazobactam in Pseudomonas aeruginosa and Enterobacterales in a reference laboratory in Lima, Peru: A cross-sectional study. [PDF]
Gómez de la Torre Pretell JC +5 more
europepmc +1 more source
Healthcare resource utilization and readmission outcomes in patients treated with ceftolozane/tazobactam: real-world insights from the multinational SPECTRA study. [PDF]
Yücel E +9 more
europepmc +1 more source
Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient Populations. [PDF]
Yücel E +7 more
europepmc +1 more source

